Management of Emetogenicity of Antibody-Drug Conjugates
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
Read More
Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions
June 24th 2024Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.
Read More
Medical experts delve into the challenges of brain metastases in HER2-positive breast cancer, exploring local therapies for targeting central nervous system metastases and emphasizing the crucial role of multidisciplinary tumor boards, collaboration with colleagues, and referrals to specialized providers in optimizing patient outcomes.
Read More
Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.
Read More
TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
June 10th 2024Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.
Read More
Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer
June 3rd 2024Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.
Read More
Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
May 20th 2024Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.
Read More
The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
May 20th 2024Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.
Read More
Looking Towards The Future of HR+/HER2- Breast Cancer
The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Read More
Practical Considerations for ADC Selection in HR+/HER2- mBC
Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.
Read More
Data Updates on Sacituzumab Govitecan
Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.
Read More
Biomarker Testing Practices in HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.
Read More
HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Read More
Addressing Disease Progression on ET: Data Updates and Ongoing Trials
A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.
Read More
Potential Approaches to Treatment Switching in HR+/HER2- mBC
Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.
Read More
Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
Read More
The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings
Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.
Read More
Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials
Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.
Read More
CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting
The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.
Read More
Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer
A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.
Read More